PDCD1 and non-small cell lung carcinoma: When researchers performed 16S rRNA sequencing of fecal samples of NSCLC patients receiving the PD-1 blockade antibody nivolumab, they found that those responsive to the treatment had greater microbial diversity and an abundance of Bifidobacterium longum, Alistipes putredinis and Prevotella copri.